REGENERON PHARMACEUTICALS, INC. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Q3 2026 revenues grew 36% to $5.1B; Dupixent (recorded by Sanofi) grew 35% to $6.5B, EYLEA HD grew 62% to $699M, Libtayo grew 51% to $550M. Regeneron expanded its Sanofi antibody collaboration: received $1.0B upfront payment (to be recognized as Q4 2026 collaboration revenue) plus up to $7.0B in future development, regulatory, and sales milestones, with equal profit-sharing on commercialized products. FDA approved Pasatru (garetosmab) for FOP in August 2026. Non-GAAP EPS jumped 70% to $20.07.
Why this rating
Sanofi $1B+$7B deal is ~1.5% of market cap upfront, meaningful; strong Q3 growth across franchise validates commercial execution; but deal structure shared profits limit upside relative to standalone development.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.